2026年3月14日, 印度在Kathua发动了600克郎的工厂, 制作重要的抗生素成分, 减少了对中国进口商品的依赖。 On March 14, 2026, India launched a ₹600 crore plant in Kathua to make a key antibiotic ingredient, cutting reliance on Chinese imports.

2026年3月14日, 联盟部长Jitendra Singh为位于查谟和克什米尔Kathua的600克郎制药厂奠定了基础, 生产Amino Cephalosporanic酸(ACA), On March 14, 2026, Union Minister Jitendra Singh laid the foundation for a ₹600 crore pharmaceutical plant in Kathua, Jammu and Kashmir, to produce Amino Cephalosporanic Acid (ACA), a key antibiotic ingredient, reducing reliance on imports, primarily from China. 由兰花制药公司在BIRAC的支持下开发,根据生产相关奖励计划,该设施预计将创造约400个直接和400个间接就业机会。 Developed by Orchid Pharma with support from BIRAC and under the Production-Linked Incentive Scheme, the facility is expected to create around 400 direct and 400 indirect jobs. 该项目支持印度在关键药物制造方面推动自力更生,加强国家健康安全,并与新的10 000桶生物药Shakti倡议保持一致。 The project supports India’s push for self-reliance in critical drug manufacturing, enhances national health security, and aligns with the new ₹10,000 crore Biopharma Shakti initiative. 官员说,它可以将Kathua定位为一个药品出口枢纽,并加强供应链的复原力。 Officials say it could position Kathua as a hub for pharmaceutical exports and strengthen supply chain resilience.